Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.53 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747168 | 0.94 | BRD4 (0.54) | BRD4BRDTMAPTSMN1; SMN2LMNA | |
| SCHEMBL19512122 | 0.88 | — | — | |
| SCHEMBL498606 | 0.74 | MAPT (0.47) | BRD4MAPTSMN1; SMN2LMNATSHR | |
| SCHEMBL8648117 | 0.74 | BRD4 (0.47) | BRD4BRDTMAPTSMN1; SMN2BCHE | |
| SCHEMBL145927 | 0.74 | MAPT (0.39) | BRD4BRDTMAPTSMN1; SMN2LMNA | |
| SCHEMBL930295 | 0.73 | MAPT (0.46) | MAPTSMN1; SMN2LMNATSHRKDM4E | |
| SCHEMBL663162 | 0.73 | MAPT (0.46) | MAPTSMN1; SMN2LMNATSHRKDM4E | |
| SCHEMBL7468907 | 0.73 | BRD4 (0.44) | BRD4BRDTMAPTSMN1; SMN2LMNA | |
| SCHEMBL8648121 | 0.72 | MAOA (0.46) | BRD4BRDTMAPTSMN1; SMN2BCHE | |
| SCHEMBL7122480 | 0.71 | MAPT (0.44) | MAPTSMN1; SMN2LMNATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717720-B2 | Modified compound of andrographolide | HEILONGJIANG ZHENBAODAO PHARMACEUTICAL CO., LTD. (CN) | 2020-07-21 | — | — | US | disclosed |
| US-10654868-B2 | Dihydropyrazole azepine compound serving as Akt inhibitor | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| EP-3470409-B1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2020-02-12 | — | — | EP | disclosed |
| US-10548883-B2 | Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2020-02-04 | — | — | US | disclosed |
| US-20190233434-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2019-08-01 | — | — | US | disclosed |
| US-20190151299-A1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | GENFLEET THERAPEUTICS SHANGHAI INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3473628-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | Medshine Discovery Inc. (CN) | 2019-04-24 | — | — | EP | disclosed |
| EP-3470409-A1 | BENZOTRIAZOLE-DERIVED AND UNSATURATED AMIDE COMPOUND USED AS TGF- R1 INHIBITOR | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2019-04-17 | — | — | EP | disclosed |
| US-20180346438-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | MEDSHINE DISCOVERY INC. (CN) | 2018-12-06 | — | — | US | disclosed |
| EP-3381912-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. (CN) | 2018-10-03 | — | — | EP | disclosed |
| US-6878720-B2 | VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | disclosed |
| WO-2002032891-A1 | FLAVAN COMPOUNDS, THEIR PREPARATION AND THEIR USE IN THERAPY | RIBOTARGETS LIMITED (GB) | 2002-04-25 | — | — | WO | disclosed |
| US-6344486-B1 | ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654868-B2 | Dihydropyrazole azepine compound serving as Akt inhibitor | AKT3, AKT2, AKT1 | BRD4 1417/4885BRDT 791/4885MAPT 1651/4885 |
| US-20190233434-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | AKT3, AKT2, AKT1 | BRD4 1417/4885BRDT 791/4885MAPT 1651/4885 |
| US-10548883-B2 | Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor | TGFBR1, TGFBR2, TGFB1 | BRD4 348/4885BRDT 155/4885MAPT 877/4885 |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | BRD4 3779/4885BRDT 690/4885MAPT 3932/4885 |
| US-10717720-B2 | Modified compound of andrographolide | CYP11B2, CYP11B1, DUSP23 | BRD4 4196/4885BRDT 2950/4885MAPT 2914/4885 |
| US-20190151299-A1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | TGFBR1, TGFBR2, TGFB1 | BRD4 428/4885BRDT 146/4885MAPT 1087/4885 |
| US-20180346438-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | CYP11B2, CYP11B1, DUSP23 | BRD4 4196/4885BRDT 2950/4885MAPT 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.